KR102979182B1 - 항종양 아스코르브산 에스테르 - Google Patents

항종양 아스코르브산 에스테르

Info

Publication number
KR102979182B1
KR102979182B1 KR1020237012737A KR20237012737A KR102979182B1 KR 102979182 B1 KR102979182 B1 KR 102979182B1 KR 1020237012737 A KR1020237012737 A KR 1020237012737A KR 20237012737 A KR20237012737 A KR 20237012737A KR 102979182 B1 KR102979182 B1 KR 102979182B1
Authority
KR
South Korea
Prior art keywords
compound
mixture
esi
mmol
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237012737A
Other languages
English (en)
Korean (ko)
Other versions
KR20230088718A (ko
Inventor
테레사 로요 바르게스
야가마레 폴 디옵
마리아 제네로사 데 로스 안젤레스 고메즈 파치오스
휴고 산탈라 가르시아
파티마 가리도 페르난데스
구이도 쿠르즈
마리아 루비에스 로요
Original Assignee
시헤네리스 파르마코스메틱스 에스.엘레.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시헤네리스 파르마코스메틱스 에스.엘레. filed Critical 시헤네리스 파르마코스메틱스 에스.엘레.
Publication of KR20230088718A publication Critical patent/KR20230088718A/ko
Application granted granted Critical
Publication of KR102979182B1 publication Critical patent/KR102979182B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237012737A 2020-09-14 2021-09-13 항종양 아스코르브산 에스테르 Active KR102979182B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
EP20382804.1 2020-09-14
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (2)

Publication Number Publication Date
KR20230088718A KR20230088718A (ko) 2023-06-20
KR102979182B1 true KR102979182B1 (ko) 2026-06-19

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012737A Active KR102979182B1 (ko) 2020-09-14 2021-09-13 항종양 아스코르브산 에스테르

Country Status (10)

Country Link
US (1) US20230278974A1 (cg-RX-API-DMAC7.html)
EP (2) EP3967684A1 (cg-RX-API-DMAC7.html)
JP (1) JP7805651B2 (cg-RX-API-DMAC7.html)
KR (1) KR102979182B1 (cg-RX-API-DMAC7.html)
CN (1) CN116724028B (cg-RX-API-DMAC7.html)
AU (1) AU2021339010A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191119A1 (cg-RX-API-DMAC7.html)
ES (1) ES3006988T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023002970A (cg-RX-API-DMAC7.html)
WO (1) WO2022053679A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120882410A (zh) * 2023-03-09 2025-10-31 至善生医股份有限公司 包含13-顺式视黄酸和抗坏血酸的缀合化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772402A (zh) 2012-08-14 2012-11-14 中山大学 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法
WO2018026673A1 (en) 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
CN101550119B (zh) * 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
JP2016104708A (ja) * 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP6588764B2 (ja) * 2015-01-26 2019-10-09 章博 田井 抗腫瘍剤
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772402A (zh) 2012-08-14 2012-11-14 中山大学 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法
WO2018026673A1 (en) 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional Foods in Health and Disease, 2019, Vol.9, No.3, pp.180-204

Also Published As

Publication number Publication date
JP2023541840A (ja) 2023-10-04
CN116724028B (zh) 2025-07-08
CN116724028A (zh) 2023-09-08
EP3967684A1 (en) 2022-03-16
JP7805651B2 (ja) 2026-01-26
EP4211123A1 (en) 2023-07-19
EP4211123B1 (en) 2024-11-06
CA3191119A1 (en) 2022-03-17
ES3006988T3 (en) 2025-03-19
WO2022053679A1 (en) 2022-03-17
EP4211123C0 (en) 2024-11-06
MX2023002970A (es) 2023-05-15
AU2021339010A1 (en) 2023-03-23
KR20230088718A (ko) 2023-06-20
US20230278974A1 (en) 2023-09-07

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)